CL2021003531A1 - Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020 - Google Patents

Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020

Info

Publication number
CL2021003531A1
CL2021003531A1 CL2021003531A CL2021003531A CL2021003531A1 CL 2021003531 A1 CL2021003531 A1 CL 2021003531A1 CL 2021003531 A CL2021003531 A CL 2021003531A CL 2021003531 A CL2021003531 A CL 2021003531A CL 2021003531 A1 CL2021003531 A1 CL 2021003531A1
Authority
CL
Chile
Prior art keywords
application
crystalline hydrate
fluorobenzyl
imidazo
triazol
Prior art date
Application number
CL2021003531A
Other languages
English (en)
Inventor
Thomas Storz
Leena Kumari Prasad
Kwame W Nti-Addae
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CL2021003531A1 publication Critical patent/CL2021003531A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se relaciona con el hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente divulgación también provee composiciones farmacéuticamente aceptables que comprenden el hidrato cristalino 2 y métodos para usar dichas composiciones en el tratamiento de diversas afecciones.
CL2021003531A 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020 CL2021003531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
CL2021003531A1 true CL2021003531A1 (es) 2022-08-19

Family

ID=65818696

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.

Country Status (20)

Country Link
US (2) US11466015B2 (es)
EP (1) EP3762389B1 (es)
JP (1) JP7423539B2 (es)
KR (1) KR20200128708A (es)
CN (1) CN111836812A (es)
AU (1) AU2019231724B2 (es)
BR (1) BR112020018212A2 (es)
CA (1) CA3092683A1 (es)
CL (5) CL2020002284A1 (es)
CO (1) CO2020012493A2 (es)
CR (1) CR20200458A (es)
EA (1) EA202092109A1 (es)
IL (1) IL276853A (es)
MA (1) MA54638A (es)
MX (5) MX2023004858A (es)
PE (1) PE20210124A1 (es)
PH (1) PH12020551394A1 (es)
SG (1) SG11202008641WA (es)
TW (1) TWI823903B (es)
WO (1) WO2019173551A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202100092QA (en) * 2018-07-11 2021-02-25 Cyclerion Therapeutics Inc USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS
CN118221651A (zh) * 2022-12-21 2024-06-21 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途
WO2024131850A1 (zh) * 2022-12-21 2024-06-27 广东东阳光药业股份有限公司 氟取代的吲唑化合物的晶型及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DK1095016T3 (da) 1998-07-08 2006-03-13 Sanofi Aventis Deutschland Svovlsubstituerede sulfonylaminocarboxylsyre-N-arylamider, deres fremstilling, deres anvendelse og farmaceutiske præparater omfattende dem
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP2197551B1 (en) 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
US8741910B2 (en) 2008-11-25 2014-06-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP5411300B2 (ja) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2564503T3 (es) 2010-05-27 2016-03-23 Merck Sharp & Dohme Corp. Activadores de la guanilato-ciclasa soluble
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
WO2015187470A1 (en) 2014-06-04 2015-12-10 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
WO2016087342A1 (de) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
DK3507291T3 (da) 2016-09-02 2021-08-30 Cyclerion Therapeutics Inc Kondenserede bicykliske sgc-stimulatorer

Also Published As

Publication number Publication date
MA54638A (fr) 2021-11-10
MX2023004855A (es) 2023-11-24
JP2021515015A (ja) 2021-06-17
EP3762389B1 (en) 2024-02-28
BR112020018212A2 (pt) 2020-12-29
CL2020002284A1 (es) 2020-11-27
US20230095799A1 (en) 2023-03-30
CA3092683A1 (en) 2019-09-12
MX2023004856A (es) 2023-11-24
TW201940487A (zh) 2019-10-16
TWI823903B (zh) 2023-12-01
CO2020012493A2 (es) 2020-10-30
EA202092109A1 (ru) 2021-03-04
WO2019173551A1 (en) 2019-09-12
AU2019231724A1 (en) 2020-10-08
CN111836812A (zh) 2020-10-27
WO2019173551A8 (en) 2020-06-11
CR20200458A (es) 2020-11-09
PH12020551394A1 (en) 2021-11-22
JP7423539B2 (ja) 2024-01-29
CL2021003530A1 (es) 2022-08-19
AU2019231724B2 (en) 2024-06-27
MX2023004857A (es) 2023-11-24
KR20200128708A (ko) 2020-11-16
CL2021000301A1 (es) 2021-06-18
SG11202008641WA (en) 2020-10-29
US11466015B2 (en) 2022-10-11
MX2023004858A (es) 2023-11-24
MX2020009183A (es) 2020-10-08
IL276853A (en) 2020-10-29
CL2021003536A1 (es) 2022-08-19
EP3762389A1 (en) 2021-01-13
US20210115050A1 (en) 2021-04-22
PE20210124A1 (es) 2021-01-19

Similar Documents

Publication Publication Date Title
CL2021003536A1 (es) Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020
MX2021007579A (es) Estimuladores de guanilato ciclasa soluble (sgc) biciclicos fusionados.
JOP20200315A1 (ar) مركبات بورينون واستخدامها في معالجة السرطان
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX2018004954A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer.
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
PE20170403A1 (es) COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER
EA030735B9 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
NZ607904A (en) Substituted imidazopyridazines
EA201691862A2 (ru) Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
PH12019501017A1 (en) Sgc stimulators
UY31588A1 (es) Derivados de imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
MX2022012523A (es) Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3- triazol-1-il)fenil]-6-oxo-1,6-dihidropirimidin-1-il}-3-(difluorom etil)-9-metil-3,4,7,15-tetraazatriciclo[12.3.1.0 2,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona.
MX2021008645A (es) Forma cristalina de un inhibidor de cinasa ciclinodependiente (cdk).
MX2021002794A (es) Metodo mejorado para la fabricacion de 3-[(1s)-1-imidazo[1,2-a]pir idin-6- iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimorficas de la misma.
MX2023008755A (es) Cristales de sal.
TN2010000390A1 (en) Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease